Ensysce Biosciences, Inc.
ENSC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001716947
In the last 90 days, Ensysce Biosciences, Inc. insiders filed 1 open-market purchase and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $261.1K in total; no superinvestor holds it.
13F holders, Q2 2022
Institutional positions in Ensysce Biosciences, Inc. as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- 0 vs. Q1 2022
- Shares held
- 3.92M
- −1.54M (−28.2%) vs. Q1 2022
- Total value
- $3.41M
- −$2.82M (−45.3%) vs. Q1 2022
- New holders
- 4
- 5 more added
- Sold out
- 4
- 2 more reduced
Compare with Q1 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ENSC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 18 | $261.1K |
| Q1 2026 | 15 | $261.5K |
| Q4 2025 | 17 | $461.1K |
| Q3 2025 | 17 | $833.7K |
| Q2 2025 | 11 | $398.8K |
| Q1 2025 | 9 | $903.4K |
| Q4 2024 | 8 | $1.15M |
| Q3 2024 | 13 | $580.5K |
| Q2 2024 | 11 | $253.0K |
| Q1 2024 | 10 | $236.5K |
| Q4 2023 | 9 | $56.4K |
| Q3 2023 | 12 | $231.1K |
| Q2 2023 | 9 | $714.0K |
| Q1 2023 | 10 | $103.2K |
| Q4 2022 | 14 | $138.2K |
| Q3 2022 | 20 | $810.7K |
| Q2 2022 | 21 | $3.41M |
| Q1 2022 | 21 | $6.23M |
| Q4 2021 | 18 | $15.9M |
| Q3 2021 | 16 | $9.56M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2022
Shares, value and share of portfolio for each institution holding Ensysce Biosciences, Inc.; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Wells Fargo & Company | 139 | $0 | 0.00% | +75+117.2% | Added |
| Morgan Stanley | 270 | $0 | 0.00% | 00.0% | Unchanged |
| Covington Capital Management | 100 | $0 | 0.00% | 00.0% | Unchanged |
| Cutler Group LP | 100 | $0 | 0.00% | 00.0% | Unchanged |
| FNY Investment Advisers, LLC | 20 | $0 | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 3,064 | $3.00K | 0.00% | −7,162−70.0% | Reduced |
| Wolverine Asset Management LLC | 4,987 | $4.00K | 0.00% | 00.0% | Unchanged |
| StoneX Group Inc. | 11,870 | $10.3K | 0.00% | +11,870 | New |
| Susquehanna International Group, LLP | 15,393 | $13.0K | 0.00% | +15,393 | New |
| UBS Group AG | 17,087 | $15.0K | 0.00% | +9,113+114.3% | Added |
| Two Sigma Securities, LLC | 24,034 | $21.0K | 0.00% | +24,034 | New |
| State Street Corp | 35,551 | $31.0K | 0.00% | 00.0% | Unchanged |
| Powell Investment Advisors, LLC | 70,000 | $61.0K | 0.04% | +20,000+40.0% | Added |
| Citigroup Inc | 70,940 | $62.0K | 0.00% | +70,940 | New |
| Vanguard Group Inc | 122,353 | $106.0K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 127,348 | $110.0K | 0.00% | +17,102+15.5% | Added |
| Anson Funds Management LP | 150,664 | $131.0K | 0.02% | −1,724,703−92.0% | Reduced |
| Stifel Financial Corp | 216,642 | $188.0K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 234,240 | $203.0K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 356,325 | $309.0K | 0.00% | +68,664+23.9% | Added |
| HG Vora Capital Management, LLC | 2,462,500 | $2.14M | 0.09% | 00.0% | Unchanged |
| Virtu Financial LLC | 0 | $0 | 0.00% | −24,630−100.0% | Sold out |
| Evergreen Capital Management LLC | 0 | $0 | 0.00% | −11,534−100.0% | Sold out |
| Cresset Asset Management, LLC | 0 | $0 | 0.00% | −11,223−100.0% | Sold out |
| FinTrust Capital Advisors, LLC | 0 | $0 | 0.00% | −350−100.0% | Sold out |